Sensei Biotherapeutics, Inc.

Informe acción NasdaqGM:SNSE

Capitalización de mercado: US$12.3m

Sensei Biotherapeutics Dirección

Dirección controles de criterios 2/4

Sensei Biotherapeutics' CEO is John Celebi, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is $1.01M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $30.63K. The average tenure of the management team and the board of directors is 1.9 years and 3.8 years respectively.

Información clave

John Celebi

Chief Executive Officer (CEO)

US$1.0m

Compensación total

Porcentaje del salario del CEO52.6%
Permanencia del CEO6.8yrs
Participación del CEO0.2%
Permanencia media de la dirección1.9yrs
Promedio de permanencia en la Junta Directiva3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14
We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18
Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16
Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Celebi en comparación con los beneficios de Sensei Biotherapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2024n/an/a

-US$30m

Mar 31 2024n/an/a

-US$32m

Dec 31 2023US$1mUS$532k

-US$34m

Sep 30 2023n/an/a

-US$39m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$513k

-US$49m

Sep 30 2022n/an/a

-US$46m

Jun 30 2022n/an/a

-US$42m

Mar 31 2022n/an/a

-US$41m

Dec 31 2021US$7mUS$487k

-US$37m

Sep 30 2021n/an/a

-US$33m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$2mUS$395k

-US$20m

Compensación vs. Mercado: John's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD655.65K).

Compensación vs. Ingresos: John's compensation has been consistent with company performance over the past year.

CEO

John Celebi (52 yo)

6.8yrs

Permanencia

US$1,012,289

Compensación

Mr. John K. Celebi, MBA serves as President, Chief Executive Officer and Director of Alvaxa Biosciences, Incorporated since February 2018. Mr. Celebi serves as President and Chief Executive Officer of Sens...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
John Celebi
President6.8yrsUS$1.01m0.25%
$ 30.6k
Edward Van der Horst
Chief Scientific Officer1.9yrsUS$739.08k0.14%
$ 17.4k
Josiah Craver
Senior VP of Financeless than a yearsin datossin datos
Lora Pike
Vice President of Investor Relations & Communicationsno datasin datossin datos
Christopher Gerry
Senior VP2.3yrssin datossin datos
Stephanie Krebs
Chief Business Officerless than a yearsin datossin datos
Aaron Weitzman
Chief Medical Officerno datasin datossin datos

1.9yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: SNSE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
John Celebi
President6.8yrsUS$1.01m0.25%
$ 30.6k
Thomas Ricks
Independent Director8.9yrsUS$75.56k1.35%
$ 166.3k
William Ringo
Independent Chairman2.7yrsUS$101.57k0.063%
$ 7.8k
Robert Holmen
Independent Director7.8yrsUS$73.39k0.084%
$ 10.4k
Richard Ulevitch
Member of Immuno-Oncology Advisory Board3.5yrssin datossin datos
Deneen Vojta
Independent Director3.8yrsUS$69.32k0.018%
$ 2.2k
James Peyer
Independent Director4.8yrsUS$68.43ksin datos
Alain Algazi
Member of Immuno-Oncology Advisory Boardno datasin datossin datos
Maura Gillison
Member of Immuno-Oncology Advisory Board3.5yrssin datossin datos
Kristian Humer
Independent Director3.3yrsUS$62.24k0.018%
$ 2.2k
Sara Pai
Member of Immuno-Oncology Advisory Boardno datasin datossin datos
Robert Schreiber
Member of Immuno-Oncology Advisory Boardno datasin datossin datos

3.8yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: SNSE's board of directors are considered experienced (3.8 years average tenure).